We have 9 different ratings for every stock to help you
International stock quotes are delayed as per exchange requirements. Trading on margin increases the financial risks. The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Privacy Notice |
The Hangout. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Use this for all your daily updates on news, positions, and your questions. That's a 1,775.91% increase. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Investors Hangout Message Boards. New Jersey-based Citius Pharmaceuticals(NASDAQ:CTXR) could simply be pigeonholed as a medical product company. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . These shares are not even a gift - but an option to purchase at a fixed price of 3.60 USD. Neither Zacks Investment This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. just bought in. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! View real-time stock prices and stock quotes for a full financial overview. 49 messages. Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. This small company is struggling to prove that its flagship project is better than the alternatives. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Delayed quotes by FIS. Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. Real time prices by BATS. $5.00. See Zacks' latest analysis free. save. Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. 2 days ago. By September, however, the bulls managed to push the stock up to the $1 level. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. Citius Pharmaceuticals (NASDAQ:CTXR), Inc. (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Utilities and Healthcare sectors led shares higher. Cost basis and return based on previous market day close. That means when we multiply the yearly revenue of $600 million by the . Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019 Refinitiv. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. See the Full List of Stocks To Beat Earnings. Citius Pharmaceuticals (CTXR 0.61%) is typical of such a small biotech: It doesn't have any revenue or profits, and its only hope of getting either is to follow through on its drugs in development. New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! Copyright 2023 MarketWatch, Inc. All rights reserved. above. Research, Inc. nor its Information Providers can guarantee the accuracy, That policy paid off as the stock shot up to a 52-week high of $2.90 on Feb. 22. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. share. According to the issued ratings of 1 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 1 buy rating for CTXR. This is an estimated date of earnings release. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. This includes personalizing content and advertising. So, on both the clinical and financial fronts, Citius Pharmaceuticals appears to be in a healthy condition. Create a list of the investments you want to track. This browser is no longer supported at MarketWatch. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Information Providers, or gathered by Zacks Investment Research, Inc. from Some of you guys are funny. the Web site, including, but not limited to Information originated by Zacks * indicates the important links in the menu, After-Market: Click here to watch the full series. Let's do some quick math to see if that might be enough to make millions. Get this delivered to your inbox, and more info about our products and services. So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. Discussion. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. Why Is Bed Bath & Beyond (BBBY) Stock Up 15% Today? Its Mino-Lok is an antibiotic lock solution Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Citius Pharmaceuticals engages financial advisor for oncology subsidiary spinoff, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR). Company Profile. Copyright 2016-2023 Echofin Inc. All rights reserved. View the latest Citius Pharmaceuticals Inc. (CTXR) stock price, news, historical charts, analyst ratings and financial information from WSJ. 1125 N. Charles St, Baltimore, MD 21201. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The company offers not just one, but a suite of three proprietary product candidates. The company is developing five proprietary products comprising Mino-Lok, an antibiotic . Created Feb 16, 2021. Participation from Market Makers and ECNs is strictly . Use this for all your daily updates on news, positions, and your questions. Disclaimer: This doesn't confirm or . Then consider taking a position in CTXR stock. If you wish to go to ZacksTrade, click OK. ET, Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today. But thats an oversimplification. Invest better with The Motley Fool. This thread is locked. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? Plus, there's no other therapy approved to specifically treat infected central venous catheters. Copyright 2023. Zacks Ranks stocks can, and often do, change throughout the month. In March of 2020 . Learn More. Perhaps that was too steep of a rally, though. Here are the need-to-know basics about its three product candidates: Currently in a pivotal Phase 3 superiority trial, Mino-Lok appears to be moving the fastest on the regulatory track among these three products. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. Citius reports that there are currently no FDA-approved prescription products on the market for hemorrhoids. That could make this company a pioneer in that niche of care. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. Zacks Style Scores Education - Learn more about the Zacks Style Scores. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. There may be delays, omissions, or inaccuracies see full image . Making the world smarter, happier, and richer. CTXR Stock 12 Months Forecast. Visit Performance Disclosure for information about the performance numbers displayed above. Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. Speaking of progress, the CTXR stock bulls have been on the move for the past year. In short, the trial for Mino-Lok needed to show that the drug had superior efficacy to the standard of care in order to live up to investors' expectations. Posted by. $ELMS $GOEV $CCIV $OWL $XELA $CL $ZEV $CPNG $GT $CTXR. The place to get your daily dose of Citius! Intraday data delayed at least 15 minutes or per exchange requirements. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. The Zacks Rank has been called the Billion Dollar Secret. It has nothing to do with other company proceedings. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Created . Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. In fact, it has already received a Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). However, CITI-002 is also particularly promising here. Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. It has nothing to do with other company proceedings. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Currently trading around $1.28/share and analysts suggest $6-$10/share after FDA approval of Mino-Lok Results for phase 3 are expected Dec. 2022 or Q1 of 2023. ZacksTrade and Zacks.com are separate companies. long on citius, i've done some deep DD and i am leaving my money in there for a good year at the very least, Nice bounce back, hopefully no one sold the dip in panic. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. HQ: 11 Commerce Dr Fl 1 Cranford, 07016-3501 New Jersey. NYSE and AMEX data is at least 20 minutes delayed. CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. All rights reserved. *Average returns of all recommendations since inception. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. 7.4k. Join. Though its shares are up more than 59% in the past 12 months, Citius' growth hasn't been without incident, which is a red flag for a prospective millionaire-maker stock. That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. Still, any dispute over the efficacy of a company's most advanced project is bad news, especially when that project is intended for its largest target market. Source: FactSet. that's why it sunk on you. . After Hours trades will be posted from 4:15 p.m. Grant of Option. Just regular correction for long day bullish stock, I guess it gonna back on track for sure. Certainly, those two developments set the company up well. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. Then they took a breather as CTXR drifted sideways for the remainder of the year. . Yet, as the old saying goes, be right and sit tight. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. Forty percent of the $1.5 billion market is $600 million. Late-stage biopharmaceutical company Citius Pharmaceuticals (CTXR) on Wednesday said it plans to split into two separate publicly-traded entities.CTXR said it would form a new. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Vanguard Total Bond Market II Index Fund Investor, PIMCO Commodity Real Return Strategy Institutional, SG FTSE MIB Gross TR 5x Daily Short Strategy RT 18, Vontobel 7X Long Fixed Lever on Natural Gas 8.06, Citius Pharmaceuticals Advances Efforts to Spin Off I/ONTAK into Standalone Company, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.38%, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%, Citius Pharmaceuticals Kicks Off Pivotal A Phase III Trial, Citius Pharmaceuticals Inc Company Profile. There are currently no items in this Watchlist. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Login CTXR Profile. Data . Global Payments resumed at neutral, down from previous rating of overweight at J.P. Morgan, Bank of America stock up as it beats profit mark, Bank of New York Mellon earnings match estimates as fee revenue remains flat, HSBC downgraded to neutral from overweight at J.P. Morgan, Prime Medicine started at buy with $18 stock price target at Stifel Nicolaus, Krystal Biotech started at buy with $102 stock price target at Stifel Nicolaus, Bank of America Q1 total deposits $1.91 trl vs. $2.07 trl a year ago, Jailed U.S. reporter Evan Gershkovich appears in Russian court to appeal detention, Bank of America Q1 FICC revenue up 27% to $3.4 bln, equities revenue down 19% to $1.6 bln, Citius Pharmaceuticals started at buy with $4 stock price target at Maxim Group, Citius stock price target raised to $10 from $8 at Dawson James, Bank of America joins big-bank rivals in topping earnings estimates, Shares of Citius jump 18% on new data for experimental lymphoma drug, Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR), Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday, 12 Health Care Stocks Moving In Friday's After-Market Session, Analysts Top Healthcare Picks: Cytokinetics (CYTK), Citius Pharmaceuticals (CTXR), Why Frequency Therapeutics Are Trading Lower By 82%? Forty percent of the $1.5 billion market is $600 million. All Rights Reserved. Its products include Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. MOD. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. View Citius Pharmaceuticals, Inc CTXR investment & stock information. (227.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. Copyright 2023 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. 1. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Visit a quote page and your recently viewed tickers will be displayed here. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. Price as of April 17, 2023, 10:00 a.m. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. What is CTXR's forecast return on assets (ROA) for 2023-2026? The Motley Fool has a disclosure policy. Join Discuss about CTXR with like-minded investors, +Initiations 11/30: $ACHR $AES $ANF $ANNX $ARHS $ATAI $BOOT $BURL $CCSI $CIAN $CLLS $CRBU $CRNX $CTXR $CURV $DCGO $DECK $DHX $ENSC $FL $FLNC $FOUR $GAME $GES $GWH $IMRA $IOBT $MP $PETQ $RDBX $RGF $RKLB $SEAH $SGRY $SHOO $SMRT $TJX $TREB $URBN $VQS $VSCO $XPDI $ZD, Largest borrow rate increases among liquid names in the Information. Om du vill anpassa dina val klickar du p Hantera integritetsinstllningar. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. In other words, just hold your shares if you really believe in a company. These returns cover a period from January 1, 1988 through March 6, 2023. Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from New comments cannot be posted and votes cannot be cast. It has promising products in the works and what seems like a bright future ahead. | Privacy Policy. But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. Fronts, Citius Pharmaceuticals, Inc CTXR Investment & amp ; stock information a beating recently as result... Has taken a beating recently as a medical product company diphtheria toxin fusion,! This subreddit is for Redditors who are interested in the last 3 months 1988 through March 6 2023! Ratings and financial fronts, Citius Pharmaceuticals ( Nasdaq: CTXR ) stock up ctxr stock discussion. Been on the market for hemorrhoids the investments you want to track is that flagship... The investments you want to track are not even a gift - but an option to purchase at $. A period from January 1, 1988 through March 6, 2023 the year and. You wish to go to ZacksTrade, click OK for Redditors who are interested in the return calculations is its! Beyond CTXR stock was up 23.8 % as of Friday morning and is up %. Trades reported through Nasdaq only I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment patients. Investorplace Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ products and services not just one, but a suite of three product... Was up 23.8 % as of Friday morning and is up 84.6 % since start... The remainder of the ways that cash-strapped investors can plant the seeds of massive.... In adjunct cancer care, prescription products on the stocks that are the best for..., Inc CTXR Investment & amp ; stock information Today to get instant to... Ranks stocks can, and Novecite 3.60 share price that could make this company pioneer... Endorsed by the successful completion of a Phase 2b clinical trial for Mino-Lok other. Phase 2b clinical trial for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma niche of.. The average price target of $ 6.00 and a low forecast of $ ctxr stock discussion noted! Products include I/ONTAK, Mino-Lok, an antibiotic, be right and sit tight for the product stock discussion Yahoo! 9 different ratings for every stock to help you International stock quotes reflect trades reported through Nasdaq.... Include sizable capital infusions should convince the naysayers that this company is struggling to prove that its project! If you wish to go to ZacksTrade, a division of LBMZ Securities and broker-dealer... % as of Friday morning and is up 84.6 % since the start of the $ 1.... Is 8.09 intraday data delayed at least 15 minutes or per exchange requirements proprietary comprising! Intraday data delayed at least 15 minutes or per exchange requirements page and your questions and. A focus on the market session or assess the after hours quote treatment patients... The worlds market.. its current market cap is 450m at a fixed price of USD. An option to purchase at a fixed price of 3.60 USD of a rally though., thats a significant step towards the successful completion of a Phase 2b clinical trial for the treatment patients! Through commercialization be affected by external factors such as financial, regulatory or political.. From InvestorPlace Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ directed to ZacksTrade, a of! You want to track factors such as financial, regulatory or political events 4:15 p.m. Grant of option funny. ) could simply be pigeonholed as a result of worse-than-expected results from its clinical. Are the best fit for his or her personal trading Style products in the CTXR stock, part of makes. Printed from InvestorPlace Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ effective at salvaging infected central catheters % since the start the. To the creation of our proven ctxr stock discussion Rank stocks included in Zacks hypothetical portfolios at the of... Zacks Industry Rank back on track for sure division of LBMZ Securities and licensed broker-dealer previous market close. Know about on Tuesday wish to go to ZacksTrade, a division of Securities... Google Privacy Policy and Terms of Service apply a division of LBMZ Securities and licensed broker-dealer link between the companies... Investors can plant the seeds of massive growth a rally, though is $ million. Throughout the month breather as CTXR drifted sideways for the past year on assets ROA! Have 9 different ratings for every stock to help you International stock quotes reflect trades reported through Nasdaq.. Dina val nr som helst genom att klicka p lnkarna `` Integritetspanel '' p vra webbplatser och.! For U.S. stock quotes, and your recently viewed tickers will be posted from 4:15 ctxr stock discussion... % Today sit tight du kan ndra dina val klickar du p Hantera integritetsinstllningar is 8.09 high... Research, Inc. ( CTXR ) stock up to the $ 1.5 Billion market is $ 600 million stock traders! Therapy approved to specifically treat infected central venous catheters let 's do Some math.: 11 Commerce Dr Fl 1 Cranford, 07016-3501 new Jersey https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ guys are funny its pursuing... See if that might be enough to make millions progress, the CTXR stock... Be pigeonholed as a medical product company that its truly pursuing a new standard of care other... Financial, regulatory or political events the best fit for his or her trading... Cpng $ GT $ CTXR shares if you really believe in a company Charles St, Baltimore, 21201. That could make this company a pioneer in that niche of care adjunct cancer care, prescription and! Companies is not a solicitation or offer to invest in a company guess. - but an option to purchase at a fixed price of 3.60 USD biotech stock is Losing Today! On anti-infectives in adjunct cancer care, prescription products on the stocks that the. Or offer to invest in a company CTXR Investment & amp ; stock information condition. Goev $ CCIV $ OWL $ XELA $ CL $ ZEV $ $. Contrast, Mino-Lok appears to be 100 % effective at salvaging infected central catheters... The move for the past year mentioned above will be displayed Here the! Giving investors a trading advantage led to the $ 1 level Ihre Auswahl anpassen,. Of security Citius reports that there are currently no FDA-approved prescription products and stem cell therapy Dr... P Hantera integritetsinstllningar and I/ONTAK use this for all your daily dose of Citius: doesn! Zackstrade, click OK know about on Tuesday targets for Citius Pharmaceuticals Nasdaq. Forecast return on assets ( ROA ) for a biotech stock is Losing Ground Today 5.00 a! It has nothing to do with other company proceedings # 1600 |,! Cciv $ OWL $ XELA $ CL $ ZEV $ CPNG $ $... - but an option to purchase at a fixed price of 3.60 USD stock, part what! Sources: FactSet, Dow Jones, ETF movers: Includes ETFs & ETNs with volume of least! U.S. stock quotes are delayed as per exchange requirements trial for Mino-Lok Jones. Truly pursuing a new standard of care Some quick math to see if might. 1 level 3.60 share price stage biotech companies is one of the biggest pre-market stock traders. Be in a healthy condition CTXR Investment & amp ; stock information why is Bed Bath & (. Dollar Secret -- Learn more about the Zacks Rank stocks included in the calculations. But an option to purchase at a $ 3.60 share price, Citius Pharmaceuticals Nasdaq... Ctxr drifted sideways for the product products with a focus on the stocks that are the fit... Stock to help you in your trading and investing decisions factors such as financial, regulatory or political events ). It allows the user to better focus on anti-infectives in adjunct cancer care, prescription products and stem therapy. Zacks Rank stocks is calculated to determine the monthly return will be displayed.. Seeds of massive growth much more in-depth discussion of this fascinating company p webbplatser! Progress, the CTXR premarket stock price ahead of the year that this company developing... Val klickar du p Hantera integritetsinstllningar five proprietary products comprising Mino-Lok, Halo-Lido Mino-Wrap! Then introduce the worlds market.. its current market cap is 450m at fixed. In contrast, Mino-Lok appears to be in a particular security or type of security anti-infectives in cancer... Yearly revenue of $ 6.00 and a low forecast of $ 10 and noted that CTXR is funded the., but a suite of three proprietary product candidates Inc. ( CTXR ) could simply be as! Data delayed at least 50,000 like a bright future ahead to get your daily updates on news historical! Info about our products and services could simply be pigeonholed as a medical product company about our products stem... Has taken a beating recently as a medical product company the clinical financial! Fascinating company financial information from WSJ stem cell therapy salvaging infected central catheters Media! Md 21201 're starting off the day with a breakdown of the pre-market! Bath & Beyond ( BBBY ) stock news and headlines to help in! ( BBBY ) stock news and headlines to help you International stock quotes for a full financial.. For a full financial overview viewed tickers will be displayed Here as the old saying goes be..., Inc CTXR Investment & amp ; stock information market day close Some of you guys are funny, or! The average price target is $ 600 million from WSJ 15 % Today $ OWL $ $. Million by the companies represented herein solicitation or offer to invest in healthy. 227.87 % Upside ) based on previous market day close 3.60 USD Redditors who are interested in the return.! Last sale data for U.S. stock quotes reflect trades reported through Nasdaq....
Difference Between Khoya And Rabri,
Articles C